Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harvard BioscienceFRA:HBI0 53 Days Payable is 51.93 as of Jun. 2026, which is 13% above its 10-year median of 45.77. GuruFocus rates FRA:HBI0 with a GF Score™ of 53/100 and a GF Value™ of €6.70. The stock has 9 warning signs investors should review. Among 793 Medical Devices & Instruments companies, Harvard Bioscience ranks worse than 66.58% on this metric.
The historical rank and industry rank for Harvard Bioscience's Days Payable or its related term are showing as below:
FRA:HBI0'
s Days Payable Range Over the Past 10 Years
Min: 37.29 Med: 45.77 Max: 50.62
Current: 49.79
During the past 13 years, Harvard Bioscience's highest Days Payable was 50.62. The lowest was 37.29. And the median was 45.77.
FRA:HBI0's Days Payable is ranked worse than 66.58% of 793
companies
in the Medical Devices & Instruments industry
Industry Median: 68.47
vs FRA:HBI0: 49.79
Harvard Bioscience's Days Payable
increased
from Jun. 2025 (50.41) to Jun. 2026 (51.93).
It may suggest that Harvard Biosciencedelayed paying its suppliers.
The historical data trend for Harvard Bioscience's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HBI0 vs RVP, MLSS, ZJYL: Days Payable Comparison
For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Bioscience Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Days Payable distribution charts can be found below:
* The bar in red indicates where Harvard Bioscience's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Harvard Bioscience's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Bioscience (FRA:HBI0) has a Days Payable of 51.93 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Harvard Bioscience and its competitors. This is 13% above median its historical median of 45.77. Over the past decade, Harvard Bioscience's Days Payable has ranged from 37.29 to 50.62. According to the industry distribution chart, Harvard Bioscience ranks #528 out of 793 companies in the Medical Devices & Instruments industry, placing it in the top 66.6%.
Is Harvard Bioscience's Days Payable too high?
Harvard Bioscience's current Days Payable of 51.93 is 13% above median its 10-year median of 45.77. Over the past 10 years, this metric has ranged from a low of 37.29 to a high of 50.62. The Medical Devices & Instruments industry median Days Payable is 68.47. Harvard Bioscience's value of 51.93 is 24.2% below this industry median. Based on the distribution chart, Harvard Bioscience ranks #528 out of 793 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Harvard Bioscience has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's Days Payable compare to RVP and MLSS?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #528 out of 793 companies for Days Payable. This places Harvard Bioscience in the lower half of its industry. The industry median Days Payable is 68.47. Harvard Bioscience's value of 51.93 is 24.2% below this benchmark. Historically, Harvard Bioscience's own Days Payable has ranged from 37.29 to 50.62 over the past decade. While the company's 10-year median is 45.77 vs. the industry median of 68.47, Harvard Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.47, based on 793 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harvard Bioscience's current Days Payable of 51.93 is 24.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Harvard Bioscience and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Bioscience's current Days Payable is 51.93, which is 13% above median its own 10-year median of 45.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current Days Payable of 51.93. The stock's GF Value™ is €6.70, compared to a current price of €4.08 — trading 39.1% below its estimated fair value. The current Days Payable is 51.93, which is 13% above median its 10-year median of 45.77 and 24.2% below the Medical Devices & Instruments industry median of 68.47. Harvard Bioscience's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current Days Payable is 51.93 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued.
The current stock price of €4.08 is trading 39.1% below its estimated GF Value™ of €6.70.
Key valuation signals for FRA:HBI0:
Days Payable: 51.93 (13% above median its 10-year median of 45.77)
GF Value™: €6.70 vs. price of €4.08 (39.1% below fair value)
Industry Position: 24.2% below the Medical Devices & Instruments median (#528 of 793)
No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
53GF Score
Get the complete analysis for FRA:HBI0
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HBI0 has been successfully added to your 
